BlossomHill presents KRAS inhibitor data
BlossomHill Therapeutics (NASDAQ:BLSM) presented preclinical findings for BH-501284, an investigational pan-KRAS inhibitor, showing activity across KRAS-mutant cancer models.
BlossomHill Therapeutics (NASDAQ:BLSM) presented preclinical findings for BH-501284, an investigational pan-KRAS inhibitor, showing activity across KRAS-mutant cancer models.
Strategy Inc (NASDAQ:MSTR) bought 1,665 Bitcoin (BTC) for $142.7 million last week.
OSI Systems (NASDAQ:OSIS) received orders of approximately $7 million from a leading industrial controls original equipment manufacturer for electronic sub-assemblies.
Merck (NYSE:MRK) entered an exclusive global license agreement with SciBrunch Therapeutics for SPR2015, a preclinical oral KRAS G12D inhibitor being developed for potential cancer treatments.
SCYNEXIS (NASDAQ:SCYX) secured a contract with the Biomedical Advanced Research and Development Authority to support development of SCY-247, with potential funding of up to approximately $214 million.
The Securities and Futures Commission (SFC) and Accounting and Financial Reporting Council (AFRC) have signed a new regulatory cooperation agreement covering financial reporting and audits.
Valley National Bancorp (NASDAQ:VLY) agreed to acquire Bluevine for approximately $340 million in a cash-and-stock transaction expected to include about 75% cash and 25% Valley common stock.
Soluna Holdings (NASDAQ:SLNH) amended its agreement with Bitdeer Technologies Group (NASDAQ:BTDR) subsidiary Dory Creek to expand Bitcoin mining operations at Soluna’s Project Kati 1 in South Texas.
TOYO (NASDAQ:TOYO) signed binding U.S. solar module supply agreements worth approximately $240 million with multiple U.S. customers since mid-June 2026.
RedotPay has completed a financial audit as it prepares for a potential US initial public offering.
GET YOUR GRAFA EDGE NOW
We'll switch on a 30-day Edge trial as a welcome gift
Got a second for a cookie? 🍪Essential cookies keep Grafa running smoothly. A few optional ones help us see what's working so we can make it better. You're in control — change your mind any time. Cookie policy · Privacy policy